Male breast carcinoma: Increased awareness needed

Breast Cancer Research

Volumn 13, Issue 5, 2011, Pages

  White, Jonathan ^a   Kearins, Olive ^b   Dodwell, David ^c   Horgan, Kieran ^a   Hanby, Andrew M ^d   Speirs, Valerie ^d  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^d UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANDROGEN RECEPTOR; AROMATASE INHIBITOR; BRCA2 PROTEIN; CHECKPOINT KINASE 2; CYTOCHROME P450 17; ESTROGEN; FULVESTRANT; GOSERELIN; LETROZOLE; PROLACTIN; TAMOXIFEN; TESTOSTERONE; BRCA2 PROTEIN, HUMAN;

ADJUVANT THERAPY; ADRENALECTOMY; ALCOHOL CONSUMPTION; AUSTRALIA; AWARENESS; BONE METASTASIS; BREAST CANCER; CANADA; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER RISK; CANCER SUSCEPTIBILITY; COWDEN SYNDROME; DEPRESSION; DRUG COST; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; GENE MUTATION; HAIR LOSS; HEALTH EDUCATION; HORMONE DETERMINATION; HUMAN; HYPOPHYSECTOMY; IMMOBILIZATION; INSOMNIA; KLINEFELTER SYNDROME; LIBIDO; LIFESTYLE MODIFICATION; LUNG METASTASIS; MALE BREAST; MALE BREAST CANCER; META ANALYSIS (TOPIC); MOOD CHANGE; NONHUMAN; ORCHIECTOMY; PATIENT COMPLIANCE; PERIPHERAL EDEMA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEX DIFFERENCE; SIDE EFFECT; SOFT TISSUE METASTASIS; TESTIS DISEASE; UNITED KINGDOM; ATTITUDE TO HEALTH; BREAST TUMOR; GENETICS; LIFESTYLE; MALE; RISK FACTOR;

AUSTRALIA; BRCA2 PROTEIN; BREAST NEOPLASMS, MALE; CANADA; ENGLAND; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; LIFE STYLE; MALE; RISK FACTORS; SCOTLAND;

EID: 80054120094     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2930     Document Type: Review

References (67)

1. All Breast Cancer Report. , http://www.cancerscreening.nhs.uk/breastscreen/all-breast-cancer-report.pdf
2. Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB, . Eds Cancer Incidence in Five Continents 2002, VIII. IARC Scientific Publication No. 155. Lyon: IACR Press, Eds.
3. Thompson D, Easton D, . Breast Cancer Linkage Consortium Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. Am J Hum Genet 2001, 68:410-419. 10.1086/318181, 1235274, 11170890, Breast Cancer Linkage Consortium.
4. Thorlacius S, Olafsdottir G, Tryggvadottir L, Neuhasen S, Jonasson JG, Tavtigian SV, Tulnius H, Ogmunsdottir HM, Eyfjord JE. A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes. Nat Genet 1996, 13:117-119. 10.1038/ng0596-117, 8673089.
5. Thorlacius S, Tryggvadottir L, Olafsdottir GH, Jonasson JG, Ogmunsdottir HM, Tulnius H, Eyfjord JE. Linkage to BRCA2 region in hereditary male breast cancer. Lancet 1995, 346:544-545. 10.1016/S0140-6736(95)91383-1, 7658781.
6. Weiss JR, Moysich KB, Swede H. Epidemiology of male breast cancer. Cancer Epidemiol Biomarkers Prev 2005, 14:20-26.
7. Brinton LA, Richesson DA, Gierach GL, Lacey JV, Park Y, Hollenback AR, Schatzkin A. Prospective evaluation of risk factors for male breast cancer. J Natl Cancer Inst 2008, 100:1477-1481. 10.1093/jnci/djn329, 2720728, 18840816.
8. Alali L, Honarpisheh H, Shaaban A, Speirs V. Conditions of the male breast: gynaecomastia and male breast cancer (Review). Mol Med Report 2010, 3:21-26. 21472195, 21472195.
9. Giordano SH, Cohen DS, Buzdar AU, Perkins G, Hortobagyi GN. Breast carcinoma in men: a population-based study. Cancer 2004, 101:51-57. 10.1002/cncr.20312, 15221988.
10. Hodgson NC, Button JH, Franceschi D, Moffat FL, Livingstone AS. Male breast cancer: is the incidence increasing?. Ann Surg Oncol 2004, 11:751-755. 10.1245/ASO.2004.01.001, 15289238.
11. Contractor KB, Kaur K, Rodrigues GS, Kulkarni DM, Singhal H. Male breast cancer: is the scenario changing. World J Surg Oncol 2008, 6:58-69. 10.1186/1477-7819-6-58, 2440380, 18558006.
12. Speirs V, Shaaban AM. The rising incidence of male breast cancer. Breast Cancer Res Treat 2009, 115:429-430. 10.1007/s10549-008-0053-y, 18478326.
13. West Midlands Cancer Intelligence Unit. , http://www.wmpho.org.uk
14. Information Services Division (Scotland). , http://www.isdscotland.org/isd/3348.html
15. Public Health Agency of Canada. , http://www.publichealth.gc.ca
16. Australian Institute of Health and Welfare. , http://www.aihw.gov.au/
17. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 2004, 4:579-591. 10.1038/nrc1408, 15286738.
18. Lahmann PH, Hoffmann K, Allen N, van Gils CH, Khaw KT, Tehard B, Berrino F, Tjønneland A, Bigaard J, Olsen A, Overvad K, Clavel-Chapelon F, Nagel G, Boeing H, Trichopoulos D, Economou G, Bellos G, Palli D, Tumino R, Panico S, Sacerdote C, Krogh V, Peeters PH, Bueno-de-Mesquita HB, Lund E, Ardanaz E, Amiano P, Pera G, Quirós JR, Martínez C, et al. Body size and breast cancer risk: findings from the European Prospective Investigation into Cancer and Nutrition (EPIC). Int J Cancer 2004, 111:762-771. 10.1002/ijc.20315, 15252848.
19. Khan N, Afaq F, Mukhtar H. Lifestyle as risk factor for cancer: evidence from human studies. Cancer Lett 2010, 293:133-143. 10.1016/j.canlet.2009.12.013, 2991099, 20080335.
20. Darbre PD, Charles AK. Environmental oestrogens and breast cancer: evidence for combined involvement of dietary, household and cosmetic xenooestrogens. Anticancer Res 2010, 30:815-827.
21. Agrawal A, Ayantunde AA, Rampaul A, Robertson JFR. Male breast cancer: a review of clinical management. Breast Cancer Res Treat 2007, 103:11-21. 10.1007/s10549-006-9356-z, 17033919.
22. De Cicco C, Baio SM, Veronesi P, Trifirò G, Ciprian A, Vento A, Rososchansky J, Viale G, Paganelli G. Sentinel node biopsy in male breast cancer. Nucl Med Commun 2004, 25:139-143. 10.1097/00006231-200402000-00008, 15154702.
23. Bagley CS, Wesley MN, Young RC Lippman ME. Adjuvant chemotherapy in males with cancer of the breast. Am J Clin Oncol 1987, 10:55-60. 10.1097/00000421-198702000-00013, 3825994.
24. Patel HZ2, Buzdar AU, Hortobagyi GN. Role of adjuvant chemotherapy in male breast cancer. Cancer 1989, 64:1583-1585. 10.1002/1097-0142(19891015)64:8<1583::AID-CNCR2820640804>3.0.CO;2-Q, 2676137, 2676137.
25. Farrow JH, Adair FE. Effect of orchidectomy on skeletal metastases from cancer of the male breast. Science 1942, 95:654. 10.1126/science.95.2478.654, 17819588.
26. Treves N. The treatment of cancer, especially inoperable cancer, of the male breast by ablative surgery (orchiectomy, adrenalectomy, and hypophysectomy) and hormone therapy (oestrogens and corticosteroids); an analysis of 42 patients. Cancer 1959, 12:820-882. 10.1002/1097-0142(195907/08)12:4<820::AID-CNCR2820120427>3.0.CO;2-9, 13663027.
27. Jaiyesimi IA, Buzdar AU, Sahin AA, Ross MA. Carcinoma of the male breast. Ann Intern Med 1992, 117:771-777.
28. Giordano SH, Buzdar AU, Hortobagyi GN. Breast cancer in men. Ann Intern Med 2002, 137:678-687.
29. Murphy CE, Carder PJ, Lansdown MR, Speirs V. Steroid hormone receptor expression in male breast cancer. Eur J Surg Oncol 2006, 32:44-47. 10.1016/j.ejso.2005.09.013, 16260112.
30. Baum M, Brinkley DM, Dossett JA, McPherson K, Patterson JS, Rubens RD, Smiddy FG, Stoll BA, Wilson A, Lea JC, Richards D, Ellis SH. Improved survival among patients treated with adjuvant tamoxifen after mastectomy for early breast cancer. Lancet 1983, 2:450.
31. Ribeiro GG. Tamoxifen in the treatment of male breast carcinoma. Clin Radiol 1983, 34:625-628. 10.1016/S0009-9260(83)80408-5, 6673881.
32. Kantarjian H, Yap HY, Hortobagyi G, Buzdar A, Blumenschein G. Hormonal therapy for metastatic male breast cancer. Arch Intern Med 1983, 143:237-240. 10.1001/archinte.143.2.237, 6824391.
33. Giordano SH, Perkins GH, Broglio K, Garcia SG, Middleton LP, Buzdar AU, Hortobagyi GN. Adjuvant systemic therapy for male breast carcinoma. Cancer 2005, 104:2359-2364. 10.1002/cncr.21526, 16270318.
34. Vinod SK, Pendlebury SC. Carcinoma of the male breast: a review of adjuvant therapy. Australas Radiol 1999, 43:69-72. 10.1046/j.1440-1673.1999.00601.x, 10901873.
35. Meguerditchian AN, Falardeau M, Martin G. Male breast carcinoma. Can J Surg 2002, 45:296-302.
36. Pasqualini JR, Chetrite G, Nguyen B-L, Maloche C, Delalonde L, Talbi M, Feinstein MC, Blacker C, Botella J, Paris J. Estrone sulfate-sulfatase and 17β-hydroxysteroid dehydrogenase activities: a hypothesis for their role in the evolution of human breast cancer from hormone-dependence to hormone-independence. J Steroid Biochem Mol Biol 1995, 53:407-412. 10.1016/0960-0760(95)00116-H, 7626488, 7626488.
37. Burstein HJ, Prestrud AA, Seidenfeld J, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Malin J, Mamounas EP, Rowden D, Solky AJ, Sowers MR, Stearns V, Winer EP, Somerfield MR, Griggs JJ. American Society of Clinical OncologyAmerican Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 2010, 28:3784-3796. 10.1200/JCO.2009.26.3756, 20625130.
38. Sasano H, Kimura M, Shizawa S, Kimura N, Nagura H. Aromatase and steroid receptors in gynecomastia and male breast carcinoma: an immunohistochemical study. J Clin Endocrinol Metab 1996, 81:3063-3067. 10.1210/jc.81.8.3063, 8768875.
39. Dakin Haché K, Gray S, Barnes PJ, Dewar R, Younis T, Rayson D. Clinical and pathological correlations in male breast cancer: intratumoral aromatase expression via tissue microarray. Breast Cancer Res Treat 2007, 105:169-175. 10.1007/s10549-006-9448-9, 17268818.
40. Giordano SH, Valero V, Buzdar AU, Hortobagyi GN. Efficacy of anastrozole in male breast cancer. Am J Clin Oncol 2002, 25:235-237. 10.1097/00000421-200206000-00006, 12040279.
41. Italiano A, Largillier R, Marcy PY, Foa C, Ferrero JM, Hartmann MT, Namer M. Complete remission obtained with letrozole in a man with metastatic breast cancer. Rev Med Interne 2004, 225:323-324.
42. Zabolotny BP, Zalai CV, Meterissian SH. Successful use of letrozole in male breast cancer: a case report and review of hormonal therapy for male breast cancer. J Surg Oncol 2005, 90:26-30. 10.1002/jso.20233, 15786432.
43. Arriola E, Hui E, Dowsett M, Smith IE. Aromatase inhibitors and male breast cancer. Clin Transl Oncol 2007, 9:192-194. 10.1007/s12094-007-0034-3, 17403631.
44. Visram H, Kanji F, Dent SF. Endocrine therapy for male breast cancer: rates of toxicity and adherence. Curr Oncol 2010, 17:17-21. 2949363, 20975874.
45. Turner KJ, Morley M, Atanassova N, Swanston ID, Sharpe RM. Effect of chronic administration of an aromatase inhibitor to adult male rats on pituitary and testicular function and fertility. J Endocrinol 2000, 164:225-238. 10.1677/joe.0.1640225, 10657858.
46. Mauras N, O'Brien KO, Klein KO, Hayes V. Oestrogen suppression in males: metabolic effects. J Clin Endocrinol Metab 2000, 85:2370-2377. 10.1210/jc.85.7.2370, 10902781.
47. Trunet PF, Mueller P, Bhatnagar AS, Dickes I, Monnet G, White G. Open dose-finding study of a new potent and selective nonsteroidal aromatase inhibitor, CGS 20 267, in healthy male subjects. J Clin Endocrinol Metab 1993, 77:319-323. 10.1210/jc.77.2.319, 8345034.
48. Doyen J, Italiano A, Largillier R, Ferrero JM, Fontana X, Thyss A. Aromatase inhibition in male breast cancer patients: biological and clinical implications. Ann Oncol 2010, 21:1243-1245. 10.1093/annonc/mdp450, 19861576.
49. Giordano SH, Hortobagyi GN. Leuprolide acetate plus aromatase inhibition for male breast cancer. J Clin Oncol 2006, 24:e42-e43. 10.1200/JCO.2006.07.2397, 16849742.
50. National Cancer Institute Clinical Trials (PDQ®). , http://www.cancer.gov/clinicaltrials/SWOG-S0511#Outline_CDR0000442919
51. Agrawal A, Cheung KL, Robertson JF. Fulvestrant in advanced male breast cancer. Breast Cancer Res Treat 2007, 101:123. 10.1007/s10549-006-9266-0, 16807672.
52. de la Haba Rodriguez JR, Porras Quintela I, Pulido Cortijo G, Berciano Guerrero M, Aranda E. Fulvestrant in advanced male breast cancer. Ann Oncol 2009, 20:1896-1897. 10.1093/annonc/mdp413, 19752001.
53. Masci G, Gandini C, Zuradelli M, Pedrazzoli P, Torrisi R, Lutman FR, Santoro A. Fulvestrant for advanced male breast cancer patients: a case series. Ann Oncol 2011, 22:985-993. 10.1093/annonc/mdr005, 21447621.
54. Agarwal PK, Tandon S, Agrawal AK, Kumar S. Highly specific sites of prolactin binding in benign and malignant breast tissue. Indian J Exp Biol 1989, 27:1035-1038.
55. Gill S, Peston D, Vonderhaar BK, Shousha S. Expression of prolactin receptors in normal, benign, and malignant breast tissue: an immunohistological study. J Clin Pathol 2001, 54:956-960. 10.1136/jcp.54.12.956, 1731342, 11729217.
56. Ferreira M, Mesquita M, Quaresma M, Andre S. Prolactin receptor expression in gynaecomastia and male breast carcinoma. Histopathology 2008, 53:56-61. 10.1111/j.1365-2559.2008.03059.x, 18613925.
57. Forloni F, Giovilli M, Pecis C, Bortolani E, Preziosi A, Barzaghi ME, Corti D, Beck- Peccoz P. Pituitary prolactin-secreting macroadenoma combined with bilateral breast cancer in a 45-year-old male. J Endocrinol Invest 2001, 24:454-459.
58. Wennbo H, Tornell J. The role of prolactin and growth hormone in breast cancer. Oncogene 2000, 19:1072-1076. 10.1038/sj.onc.1203349, 10713692.
59. Clevenger CV, Gadd SL, Zheng J. New mechanisms for PRLr action in breast cancer. Trends Endocrinol Metab 2009, 20:223-229. 10.1016/j.tem.2009.03.001, 19535262.
60. Speirs V, Shabban AM, Pollock S, Hanby AM, Ball GR, . The Male Breast Cancer Consortium Male versus female breast cancer: study of 523 matched cases reveals differences behind similarity [abstract]. J Pathol 2010, 222:s8. The Male Breast Cancer Consortium.
61. Castellano I, Allia E, Accortanzo V, Vandone AM, Chiusa L, Arisio R, Durando A, Donadio M, Bussolati G, Coates AS, Viale G, Sapino A. Androgen receptor expression is a significant prognostic factor in oestrogen receptor positive breast cancers. Breast Cancer Res Treat 2010, 124:607-617. 10.1007/s10549-010-0761-y, 20127405.
62. Iredale R, Brain K, Williams B, France E, Gray J. The experiences of men with breast cancer in the United Kingdom. Eur J Cancer 2006, 42:334-341. 10.1016/j.ejca.2005.09.027, 16377181.
63. John W Nick Foundation. , https://malebreastcancer.org/Home_Page.php
64. Callari M, Cappelletti V, De Cecco L, Musella V, Miodini P, Veneroni S, Gariboldi M, Pierotti MA, Daidone MG. Gene expression analysis reveals a different transcriptomic landscape in female and male breast cancer. Breast Cancer Res Treat 2011, 127:601-10. 10.1007/s10549-010-1015-8, 20625818, 20625818.
65. Johansson I, Nilsson C, Berglund P, Strand C, Jönsson G, Staaf J, Ringnér M, Nevanlinna H, Barkardottir RB, Borg A, Olsson H, Luts L, Fjällskog ML, Hedenfalk I. High-resolution genomic profiling of male breast cancer reveals differences hidden behind the similarities with female breast cancer. Breast Cancer Res Treat 2011, 129:747-60. 10.1007/s10549-010-1262-8, 21113657, 21113657.
66. Speirs V, Pollock S, Shaaban AM, Hanby AM. Problems (and solutions) in the study of male breast cancer. Rare Tumors 2010, 2:e28. 2994508, 21139830, 21139830.
67. Korde LA, Zujewski JA, Kamin L, Giordano S, Domchek S, Anderson WF, Bartlett JM, Gelmon K, Nahleh Z, Bergh J, Cutuli B, Pruneri G, McCaskill-Stevens W, Gralow J, Hortobagyi G, Cardoso F. Multidisciplinary meeting on male breast cancer: summary and research recommendations. J Clin Oncol 2010, 28:2114-2122. 10.1200/JCO.2009.25.5729, 2860409, 20308661.